Immunotherapy for Ovarian Cancer

Recruiting in Palo Alto (17 mi)

+8 other locations

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)

No Placebo Group

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating activity of the combination of these agents.

Eligibility Criteria

This trial is for patients with recurrent ovarian, fallopian tube, or peritoneal cancer who have completed first-line treatment and may have had subsequent chemotherapy. They should be able to perform daily activities (ECOG 0-1), have a life expectancy of at least 6 months, measurable disease, and no history of certain autoimmune diseases or other serious conditions.

Inclusion Criteria

You meet the specific lab test requirements outlined in the study.

My cancer is getting worse, shown by tests or scans.

My cancer can be measured and I agree to have tumor biopsies before and during treatment.

+4 more

Exclusion Criteria

I have not received vaccines or drugs targeting immune checkpoints or IDO inhibitors.

I have received a live vaccine recently.

I have a skin or blood vessel disorder.

+14 more

Participant Groups

The study tests the combination of DPX-Survivac therapy with low dose oral cyclophosphamide and IDO1 inhibitor epacadostat in patients. It aims to assess safety and how well these treatments can modulate the immune system against cancer cells.

2Treatment groups

Experimental Treatment

Group I: Arm 2Experimental Treatment2 Interventions

DPX-Survivac, Cyclophosphamide (in Phase 2 only)

Group II: Arm 1Experimental Treatment3 Interventions

DPX-Survivac, Cyclophosphamide, Epacadostat (Phase 1 and initially Phase 2)

DPX-Survivac is already approved in United States, European Union, Canada for the following indications:

🇺🇸 Approved in United States as DPX-Survivac for: